The draft LCD is posted to the Medicare Coverage Database on the Centers for Medicare and Medicaid Services (CMS) website. It will go through Medicare's review process, which includes a public comment period, finalization and notification....................
today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX prostate cancer test. The draft LCD recommends coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States "to help determine which patients with early-stage, needle biopsy proven prostate cancer, can be conservatively managed rather than treated with definitive surgery or radiation therapy."
"We are very pleased with this draft coverage determination. It is an important step toward ensuring that all prostate cancer patients covered by Medicare, which represents 50 percent of the population eligible for our test, have access to the unique biological information provided by Oncotype DX in order to more precisely assess their cancer's aggressiveness and for their physicians to determine the optimal treatment," said Kim Popovits, chairman of the board, chief executive officer and president of Genomic Health.
Todays PR - UCSF-led Study Shows Oncotype DX(R) and MRI May Provide Independent Information in Favorable Risk Prostate Cancer Presentation at American Urological Association 2015 Annual Meeting Reconfirms Oncotype DX Genomic Prostate Score as Independent Predictor of Adverse Pathology
For the first time, we looked at the association between information provided by a genomic assay and a prostate MRI to better understand the value these two technologies bring to clinical practice," said Michael Leapman, M.D., lead investigator from UCSF. "These new data show that, in some patients, further risk stratification may be possible, and tools such as GPS may add important biological information to more precisely assess the aggressiveness of a patient's cancer."
Shows Ability to Accurately Monitor Urine for Presence of rbl;adder Cancer - PR
Positive Results Presented at AUA Demonstrate Company's Refined Methods Can Detect Tumor Specific DNA Markers to Enable Urine-based Monitoring for Bladder Cancer Recurrence
Proof-of-Concept Study Accepted for Presentation at AACR Precision Medicine Meeting in June
A non-invasive, urine-based test for monitoring patients for disease recurrence can improve bladder cancer patient care by optimizing the use of cystoscopies," said Matthew J. Resnick, M.D., assistant professor and urologic surgeon, Vanderbilt University Medical Center, Nashville, Tenn. "A liquid biopsy could make it less stressful for low-risk patients to comply with active surveillance, while aiding in earlier detection and more timely treatment of high-grade recurrences."
Fridays Press Release had little to nothing to do with the trading and market conditions. Friday was options expiration day. Good Luck
Oncotype Prostate Cancer Test Improves Risk Assessment for One in Four Men and Reduces Overall Healthcare Costs
Data Presented at American Urological Association Annual Meeting Underscore Test's Value to Physicians, Patients and U.S. Healthcare System
results from three studies that show the real-world positive impact of the Oncotype DX® Genomic Prostate Score (GPS) and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients. The data were presented at the 2015 American Urological Association (AUA) Annual Meeting in New Orleans.
Genomic Health has had a salesforce and footprint in Europe since breast Cancer indication. There are few "free shares". GHDX did a buyback 3years ago and the float is very low . I am not trying to be confrontive on your points, I laying blame on the companies failure to produce revenues that should have been coming in this year. Revenue growth is now not on track to make them profitable this year. There are more questions than answers with a company that has few retail shareholders. The invitae connection is very strong We shall see...Good Luck
It may look backwards to you since you are forward looking from here. Because the guidance of 2 years ago failed to produce the expected revenues that should of already started., an investor can be skeptical. I am a long, and I think the price appreciation for shareholders will not come from revenues but from a takeover. One by one the Bakers build these bios up setup the structure and move em out. All the pieces are in place Good Luck
Long position from long ago but today is so silly , I just had to , not much (700 under 26 ) ...but I just had to.
I wonder who sold 1300 shares that lowered the stock by $ 1.33 ;- ) Good luck
Invitae adopted a different approach that not only allows consumers to simply send a sample and get results, but also mandates the test to pass through a medical expert. InVitae Corp (NYSE:NVTA)’s popularity is growing day by day. It conducted 200 billable tests in 1Q2014, and orders surged to 1,100 in 3Q and 1,800 in 4Q2014. Invitae also fetched success with health-care providers. It got approval as a Medicare provider and now is in the process of signing contracts with SelectHealth and Blue Shield.
They held about 30% of that company. If you read or listened to the call yesterday ....InVitae
I was wondering if Kim just got lost counting her pile of options. Double it when GHDX gets sold.
Kim Popovits, Chairman of the Board, Chief Executive Officer & President, will present at the Bank of America Merrill Lynch 2015 Healthcare Conference in Las Vegas on Tuesday, May 12 at 3:40 p.m. Pacific Time (PT).
Supporting Wider Adoption and Reimbursement = Co PR this am